Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Phase:
PHASE2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
American River Nutrition, LLC National Cancer Institute (NCI)